Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) are important milestones in the development of tumor‐targeted therapy and have greatly improved outcomes for NSCLC patients. The gene discussed is EGFR; the disease is neoplasm.